Breast Cancer Trial, Not Yet Recruiting NCT07487844 Sponsor: University of California, San Francisco Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Not Yet Recruiting

NCT07487844
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with breast cancer that has spread to other parts of the body, confirmed by a tissue or cell sample.
  • People who have at least one soft tissue tumour (in or just under the skin) that measures between 1 cm and 5 cm, can be seen on imaging, and can be safely reached for treatment; up to 3 such tumours may be treated.
  • People who have received any amount of prior or ongoing cancer treatment, but whose treating doctors agree it is medically safe for them to pause their systemic (whole-body) breast cancer therapy for one week before the procedure and two weeks after.
  • People aged 18 years or older.
  • People with a general health and activity level rated at 0, 1, or 2 on the ECOG scale, meaning they are able to carry out at least some daily activities (confirm with trial site).
  • People whose blood counts meet the required levels: a neutrophil count of at least 1,500 per microlitre and a platelet count of at least 100,000 per microlitre.
  • People who are not currently taking blood-thinning or anti-clotting medications, or who are able to safely pause these medications in line with standard radiology procedure guidelines.
  • People living with HIV who are on effective treatment and have had an undetectable viral load within the past 6 months, as recorded in their medical file.
  • People with chronic hepatitis B who are on treatment and have an undetectable viral load, as recorded in their medical file.
  • People with a history of hepatitis C who have been successfully treated and cured, or who are currently on hepatitis C treatment with an undetectable viral load as recorded in their medical file.
  • People who have had or currently have another type of cancer, where that cancer or its treatment is not expected to interfere with the safety or results of this trial.
  • People of reproductive potential who agree to use adequate contraception (such as hormonal or barrier methods, or abstinence) throughout the study and for 4 weeks after the last treatment, and who agree to inform their treating doctor immediately if pregnancy occurs or is suspected.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have not yet recovered from side effects of prior or current cancer treatment, where those side effects remain above a moderate level (confirm with trial site).
  • People who have a pacemaker or any other electronic implanted device.
  • People who are unable or unwilling to receive moderate sedation and local anaesthetic, or for whom these are medically unsuitable.
  • People who are currently pregnant, due to unknown risks the treatment may pose to a developing baby.
  • People who are currently breastfeeding or chestfeeding, due to unknown risks to nursing infants; the trial requires that breastfeeding or chestfeeding be stopped before treatment begins.
  • People who have any medical condition or personal circumstance that, in the opinion of the treating investigator, would make it difficult to follow the study procedures.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ryan Kohlbrenner, MD, University of California, San Francisco

Phone: 877-827-3222

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 August 2026
Est. completion
1 August 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Proportion of participants with treatment-emergent adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov